Analysts Offer Predictions for 23448 (LAB.TO)’s FY2023 Earnings (TSE:LAB)

23448 (LAB.TO) (TSE:LABFree Report) – Equities research analysts at Alliance Global Partners dropped their FY2023 earnings per share (EPS) estimates for shares of 23448 (LAB.TO) in a research report issued on Wednesday, November 15th. Alliance Global Partners analyst A. Grey now expects that the company will earn ($0.04) per share for the year, down from their prior estimate of ($0.01). Alliance Global Partners also issued estimates for 23448 (LAB.TO)’s Q4 2023 earnings at ($0.01) EPS and FY2024 earnings at ($0.02) EPS.

23448 (LAB.TO) Price Performance

About 23448 (LAB.TO)

(Get Free Report)

Fluidigm focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, it develops, manufactures, and markets multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies.

Featured Stories

Earnings History and Estimates for 23448 (LAB.TO) (TSE:LAB)

Receive News & Ratings for 23448 (LAB.TO) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 23448 (LAB.TO) and related companies with's FREE daily email newsletter.